Trial Profile
Phase I Trial of Cediranib (AZD2171), An Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myeloid Leukemia (Acute Myeloid Leukemia Accrual Closed as of 02/19/10)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Acute myeloid leukaemia; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Liver cancer; Neuroblastoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacokinetics
- 07 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2011 Planned end date changed from 1 Apr 2006 to 1 Oct 2011 as reported by ClinicalTrials.gov.